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Clozapine was the first atypical neuroleptic to be developed, and 
has been used since the 1960s. It is well known as the treatment 
of ‘last resort’.1,2 In clinical practice there is often reluctance to 
switch individuals to this medication because of its side-effect 
profile, despite its proven efficacy even in treatment-resistant 
schizophrenia.3 
The adolescent and child psychiatry unit at the University of 
Malaya Medical Centre, Kuala Lumpur, has a section that 
specifically caters for children diagnosed with early-onset 
psychosis. The unit is currently treating 3 adolescents with 
clozapine (the number is increasing). One of these cases will be 
described in this report.
Case report
A 15-year-old Chinese girl was brought to the unit by her parents 
in 2008. She had been treated by a private psychiatrist for over 
a year, and had been receiving an atypical antipsychotic. Her 
parents felt that she had done fairly well initially, but her condition 
worsened. She was suspicious of her classmates and felt that 
they were constantly making comments about her, and also 
complained that she could not trust her friends. Her parents were 
worried that she would act on these suspicions. She was unable to 
concentrate on her lessons and her grades deteriorated. At home 
the situation was no better – she told her parents that she hated 
them, even accused her father of raping her, and was angry with 
her mother for not believing this. She was irritable and had a lot to 
say when spoken to. She also complained that her eyelids were 
not wide enough and that she needed to go for an operation to 
widen them. She wore a lot of make-up and thick clothing. She 
also had sleep problems, staying up at night, reading magazines 
and watching television until the early hours of the morning. 
During the mental state examination the patient denied 
experiencing any auditory hallucinations, but was noted to be 
speaking to herself.
Even with good compliance with medication the patient’s 
symptoms worsened. It was decided that the best option was 
to switch to another atypical antipsychotic. However, after 2½ 
months, although she was sleeping better, she became more 
aggressive and her parents were afraid of her frequent outbursts. 
It was decided to try another atypical antipsychotic, but despite 
increasing the dose of the medication and allowing sufficient time 
for it to have an effect, no improvement was noted. It was then 
decided to try clozapine. 
The patient had had no previous medical illnesses of note. There 
was no history of substance use, and no significant family history 
of mental illness. A computed tomography scan of the brain and 
the results of relevant routine blood tests were normal. 
After a week on clozapine, the patient seemed calmer and 
began to socialise appropriately with her family. She remained 
in the ward for another week and was eventually discharged 
on 150 mg clozapine at night. During subsequent follow-up 
she was found to be calm and had no psychotic features. She 
was eventually able to start going to school again. Her parents 
were happy with her improvement, and her blood parameters 
remained within normal limits. 
Discussion
Early-onset schizophrenia is defined as onset before the age of 
18 years, with very early onset before the age of 13 years.4 It 
is often a terrifying and debilitating condition, and costly for the 
child and the family. Reports have suggested that the outcome is 
not generally favourable and that it is a progressively deteriorating 
developmental disorder, with up to 25% having a full remission 
with a good prognosis, another 25% showing partial remission, 
and up to 50% becoming chronic.4-6 Individuals receiving 
treatment for a first episode of schizophrenia often demonstrate a 
lasting response to antipsychotic medications, though a subgroup 
are left with significant persisting psychotic symptoms.7-9 The focus 
during recent years has been on improving understanding of the 
illness and ultimately more effective intervention.
Reports have demonstrated the efficacy of clozapine.10,11 
Unfortunately the therapeutic benefits may be accompanied by 
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severe adverse effects in children.3,11,12 The most serious side-effect 
is bone marrow suppression and agranulocytosis, which has 
delayed the acceptance of clozapine into clinical practice.13 
However, failure to treat children who do not respond to routine 
treatment because of a fear of side-effects is not justifiable, as 
the risk of not treating schizophrenia is more serious than the 
adverse effects of treatment. Furthermore, a delay in treatment 
is often associated with poor results, as the longer the duration 
of untreated psychosis the worse the condition becomes, with 
functional outcome declining sharply.7,14 The persistent negative as 
well as positive symptoms are destructive to a child’s development, 
to progress at school and to family and peer relationships, as 
was demonstrated in our case. The suicide rate in patients with 
childhood-onset schizophrenia has also been noted to be higher 
than in non-schizophrenics.6 Early treatment therefore has the 
potential to reduce the secondary impacts of this serious mental 
illness.5 In our case the onset of frequent episodes of aggression, 
which significantly affected the child’s functioning, as well as the 
imminent potential harm to others indicated a need for immediate 
pharmacological intervention. Clearly the symptoms were not 
responding to the antipsychotics used.   
Clozapine has value in the salvage of patients considered 
resistant to treatment, even in the paediatric population.10,15 It is the 
only drug licensed for the treatment of schizophrenia in individuals 
as young as 16 years who are unresponsive to or intolerant of 
conventional medication.16 Treatment-resistant patients are those 
who fail to respond to trials of two typical antipsychotics, or 
in this age of newer atypical antipsychotic agents who fail to 
experience a substantial reduction in psychopathology with at 
least three different antipsychotic agents.3,17
Although clozapine has the potential to cause severe side-effects, 
there is increasing evidence to advocate its use in the early 
treatment of first-episode patients whose psychosis does not 
remit with other second-generation antipsychotics.1 It has been 
suggested that clozapine should be positioned as a second-line 
treatment for first-episode schizophrenics who fail one trial of a 
second-generation antipsychotic.1,18,19
The most frequent side-effects observed are drowsiness, drooling, 
nonspecific excitatory changes on the electro-encephalogram 
(EEG), transient psychomotor agitation and eosinophilia.12,20 
General guidelines for using clozapine in children are the same 
as for adults, but since there is a higher rate of side-effects 
in children, clozapine must be used with extra caution in the 
paediatric population, and close monitoring for adverse events 
is essential. Monitoring of the white blood cell count is similar to 
that in adults, i.e. blood counts should be done weekly for the 
first 6 months of treatment and every second week thereafter. It is 
prudent to do a baseline test, and to include a baseline EEG. It 
is also recommended that lower doses of antipsychotics than in 
adults be used to achieve a therapeutic response.3 ‘Start low, go 
slow, taper slow’ dosing strategies are especially important when 
atypical antipsychotic agents are tried on adolescents.3 The long-
term outcome in treatment-resistant children seems to be predicted 
best by the improvement seen at 6 weeks, by which time most 
progress will have occurred.10,21 This was noted in our case.
Bipolar disorder typically presents with affective and at times 
psychotic symptoms. Mania in adolescents can therefore present 
with psychotic symptoms, i.e. delusions, hallucinations and 
thought disorder.22 Our patient demonstrated prominent delusions 
of reference and persecution, and although she denied hearing 
any voices, she was seen talking to herself. There were no 
overt manic or depressive symptoms, although she did display 
irritability. The diagnosis of schizophrenia rather than a psychotic 
mood disorder was therefore made. However, longitudinal 
assessment is needed to ensure accuracy of diagnosis in all such 
cases.23
As our child mental health services increase, we are likely to see 
more children with early-onset treatment-resistant schizophrenia. It 
is hoped that this report will add to the current body of knowledge 
and encourage clinicians in this part of the world to use clozapine 
for the benefit of our child patients. More than 15 studies have 
demonstrated the antipsychotic efficacy of clozapine in childhood 
and adolescent schizophrenia.24 The main advantages of 
clozapine treatment in this age group in comparison with typical 
antipsychotics are: (i) good antipsychotic efficacy during an 
acute schizophrenic episode; (ii) better improvement in chronic 
cases with a high load of negative symptoms; and (iii) markedly 
fewer extrapyramidal adverse effects, and therefore fairly good 
tolerability.6,25
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